



Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis

Emanuela Pesce^a, Nicoletta Pedemonte^a, Alberto Leoni^b, Alessandra Locatelli^b, Rita Morigi^{b,*}

^a U.O.C. Genetica Medica, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147 Genova, Italy

^b Dipartimento di Farmacia e Biotecnologie, Università di Bologna, Via Belmeloro 6, 40126 Bologna, Italy

ARTICLE INFO

Keywords:

Cystic fibrosis
F508del-CFTR
Ion channels
Thiazole derivatives
Structure-activity relationships

ABSTRACT

Cystic fibrosis is a genetic disease caused by loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator gene, encoding for CFTR protein. The most frequent mutation is the deletion of phenylalanine at position 508 (F508del), which leads to distinct defects in channel gating and cellular processing. In last years, several thiazole containing small molecules, endowed with dual F508del-CFTR modulator activity, proved to be able to target these defects. In search of new chemical entities able to restore CFTR function, we designed and synthesized a small series of sixteen thiazole derivatives. The designed compounds were studied as correctors and potentiators of F508del-CFTR. Although none of the molecules showed significant corrector activity, compounds **10** and **11** exhibited potentiator effects, thus allowing to determine some basic structural features which enable to obtain F508del-CFTR potentiator activity. *In silico* ADME studies showed that these derivatives obey Lipinski's rule of five and are expected to be orally bioavailable. Therefore, these molecules may represent a good starting point for the design of analogues endowed with improved CFTR potentiator activity and a good pharmacokinetic profile.

Introduction

Cystic fibrosis (CF) is a life-threatening genetic disease caused by loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (*cftr*) gene, encoding for CFTR protein.¹ CFTR functions as a cAMP-regulated chloride channel at the apical membrane of epithelia and the disease affects the lungs, pancreas, liver, exocrine glands and other organs. More than 2000 mutations have been described in the *cftr* gene, however the most frequent is the deletion of phenylalanine at position 508 (F508del). F508del-CFTR displays several defects at the molecular level, including misfolding that results in premature degradation by the proteasome,² and if trafficked to the plasma membrane, reduced stability due to peripheral protein quality control mechanisms³ and low open probability.⁴ Thus, this kind of mutation leads to distinct defects in channel gating and cellular processing. Drug-like small molecules, known as 'CFTR modulators', can target these specific defects and restore, at least partially, CFTR function.⁵ In particular, correctors are compounds able to improve mutant CFTR folding and thus increasing protein maturation and trafficking to the plasma membrane.⁵ Potentiators are instead compounds able to stimulate activity of mutant CFTR channel with gating defect, but correctly expressed on the cell surface.⁵ While potentiators are thought

to directly bind to CFTR to enhance its open probability, correctors may act through different mechanisms of action.⁵ Depending on their target, correctors can be divided into: i) pharmacological chaperones, that act directly on mutant CFTR to stabilize its folding; and ii) proteostasis regulators, able to modify the proteostasis environment, leading to beneficial effects on CFTR maturation and trafficking to the plasma membrane.⁵ VX-809⁶ or Lumacaftor™ (Vertex Pharmaceuticals Inc) was the first corrector drug to be approved by the FDA and is combined with the potentiator Ivacaftor™ (VX-770)⁷ (Fig. 1) in the drug Orkambi™ (Vertex Pharmaceuticals Inc) to treat CF patients homozygous for the F508del mutation.⁸ High-throughput screening of large chemical libraries and *in silico* approaches have led to the identification of several chemical entities able to act as mutant CFTR correctors and/or potentiators, among which thiazoles are particularly interesting (Fig. 1).^{9–12}

Thiazole is a well-known five-membered heterocyclic compound. This scaffold is very versatile and widely used by the industry and pharmaceutical academic researchers in the design of drugs with analgesic, anti-inflammatory, antimicrobial, antiviral, antioxidant, diuretic, anticonvulsant, neuroprotective and antitumor activity.^{13–15} In 2005, Verkman and colleagues disclosed the first F508del corrector ever identified, corr-4a (Fig. 1).⁹ Further optimization led to improved

* Corresponding author.

E-mail address: rita.morigi@unibo.it (R. Morigi).

<https://doi.org/10.1016/j.bmcl.2020.127473>

Received 30 June 2020; Received in revised form 24 July 2020; Accepted 4 August 2020

Available online 09 August 2020

0960-894X/ © 2020 Elsevier Ltd. All rights reserved.




Fig. 1. CFTR modulators: VX-809, VX-770 and some thiazole derivatives.

thiazole-containing correctors, including conformationally-locked bi-thiazoles, pyrazolylthiazoles and triazolo-bithiazoles.^{9,16–18} VX-809 also was obtained after a lead optimization process, starting from a thiazole-containing lead compound, named VRT-768 (Fig. 1).⁶ In addition, some aminoarylthiazole (AATs) derivatives exhibit dual F508del modulator ability, being correctors and/or potentiators of the channel (Fig. 1),^{19–21} and thiazole based compounds proved also to act as multitarget agents useful in CF.^{22,23} Therefore, thiazole can be considered an interesting framework for the design of small molecules addressed to overcome the underlying defects in the cellular processing and chloride channel function of CF. Indeed, the thiazole ring possesses a quite simple structure and electronic properties that allow to extend the synthesis to new molecules.¹³

On this basis, we designed a small series of thiazole derivatives (Fig. 2), inspired to well known CFTR modulators (Fig. 1), but endowed with a simplified structure, which was progressively decorated in order to get some basic SAR information. Specifically, the thiazole derivatives bear at position 2 a benzamido group, which is contained in known CFTR modulators⁹ and an acetic residue at position 4. The benzamido group can be unsubstituted, or bear a halogen or methoxy groups, substituents present in various CFTR modulators previously described. Both the ethylacetate (1–4) and the acetic acid derivatives (5–8) were considered. Furthermore, the effect of the introduction of an ethyl group at the benzamide nitrogen was investigated (8–16). Finally, since pharmacokinetic properties have to be carefully evaluated in designing compounds potentially used in therapy, we considered also this important aspect and proceeded to obtain molecules consistent with the Lipinski's rule of five. All the designed compounds (1–16) were studied as correctors and potentiators of F508del-CFTR.

Results

Chemistry

The synthetic route to the designed compounds is reported in Scheme 1. The ethyl ester of the 2-(2-aminothiazol-4-yl)acetic acid (17) was prepared according to literature²⁴ in order to protect the carboxylic group. Then, compound 17 was treated with the appropriate benzoyl

chloride, in presence of DMAP and Et₃N, to obtain the corresponding benzamides (1–4), which in turn, treated with NaOH in EtOH, gave the acetic acid derivatives 5–8. Compounds 9–12 were obtained by treating benzamides 1–4 with EtBr in presence of NaH, and treated with NaOH in EtOH to give the corresponding acids 13–16. The structure of the new derivatives (9–16) was confirmed by ¹H NMR, ¹³C NMR spectroscopy and high resolution mass spectrometry (HRMS). Detailed synthetic procedures and spectra of the new compounds are reported in the Supplementary data section.

A bibliographic survey performed using Reaxys database (<http://www.reaxys.com>) showed that the synthesis of compounds 1–3 and 5–7 was already reported, although these compounds were studied as VEGFR and PI3K kinases (1, 2, 5 and 6)²⁵ or Xa factor (3, 7) inhibitors.²⁶ Furthermore, the Reaxys database reports compounds 4 and 8 as commercially available, however we have described the synthesis and the experimental data of these compounds, since they are not reported in the literature.

Biological evaluation of thiazole derivatives as CFTR modulators


The ability of thiazole derivatives 1–16 to correct the basic defects associated to F508del mutant was tested on immortalized CFBE41o-bronchial epithelial cells stably expressing F508del-CFTR and the halide-sensitive yellow fluorescent protein (HS-YFP). The compounds were first tested as correctors, i.e. for their ability to correct the trafficking defect of mutant CFTR. To this aim, cells were incubated for 24 h with vehicle alone (DMSO), or with test compounds at two concentrations (2 and 10 μ M), or with corrector VX-809 (1 μ M) as positive control. At the time of the assay, the activity of F508del-CFTR in the plasma membrane was stimulated with forskolin (an adenylyl cyclase activator, to increase intracellular cAMP content; 20 μ M) plus the potentiator VX-770 (1 μ M), to overcome the gating defect of mutant CFTR. Determination of F508del-CFTR activity was then performed by measuring the rate of HS-YFP quenching caused by iodide influx. Treatment with the thiazole derivatives did not cause any significant increase of the ion transport activity as compared to the one detected in cells treated with vehicle (Fig. 3).

Test compounds 1–16 were then evaluated for their ability to potentiate F508del-CFTR activity upon acute stimulation. Thus, CFBE41o-

1-16

Comp.	R	R ¹	R ²	Comp.	R	R ¹	R ²
1		H		9			
2		H		10			
3		H		11			
4		H		12			
5		H	H	13			H
6		H	H	14			H
7		H	H	15			H
8		H	H	16			H

Fig. 2. Designed thiazole derivatives.



Scheme 1. Synthesis of the designed compounds (1–16). Reagents and Conditions: a) CH_2Cl_2 , DMAP, Et_3N , room temperature; b) EtOH , NaOH 2 N, room temperature; c) DMF , NaH , room temperature, then EtBr 90 °C.




Fig. 3. Activity of novel thiazole derivatives as F508del-CFTR correctors. The bar graphs report F508del-CFTR activity in CFBE41o-cells after treatment for 24 h with the indicated compounds (2 and 10 μ M). Activity was elicited by acute (20 min) treatment with forskolin (fsk, 20 μ M) plus the potentiator VX-770 (1 μ M) and subsequently measured with the HS-YFP assay. The dotted lines indicate the level of activity in cells treated with vehicle alone (DMSO, negative control) and with the positive control, corrector VX-809 (1 μ M). Data are reported as mean \pm SD (n = 3).




Fig. 4. Activity of novel thiazole derivatives as F508del-CFTR potentiators. The bar graphs report F508del-CFTR activity in CFBE41o-cells, incubated at 32 $^{\circ}$ C for 24 h to rescue defective mutant CFTR maturation, after acute treatment with the indicated compounds (2 and 20 μ M). Activity was measured with the HS-YFP assay. The dotted lines indicate the level of activity in cells treated with forskolin alone (DMSO, negative control) and with the positive control, potentiator VX-770 (1 μ M). Data are reported as mean \pm SD (n = 3). **P < 0.01 versus control (ANOVA with Dunnett's post hoc test).

cells were incubated for 24 h at 32 $^{\circ}$ C to promote correction of the trafficking defect of F508del-CFTR and its expression in the plasma membrane, and then cells were assayed following acute treatment (20 min) with test compounds (2 and 20 μ M) in the presence of forskolin (20 μ M) to increase intracellular cAMP content. The ion transport activity detected under these conditions was compared to the one measured in cells treated with forskolin alone (negative control) or with forskolin plus the potentiator VX-770 (1 μ M; as a positive control). Significant increase of the halide influx was observed when cells were acutely stimulated with thiazoles **10** and **11** (Fig. 4).

Next, the hits were submitted to an in depth analysis to evaluate their potency and efficacy. To this aim, hits were tested as potentiators at multiple concentrations in the range 80 nM–50 μ M on CFBE41o-cells, after rescue of the maturation defect at 32 $^{\circ}$ C for 24 h. Hits were found to be active in the low micromolar range, although the efficacy was lower than the positive control, potentiator VX-770 (Fig. 5).

In order to confirm specific activation of mutant CFTR by analogs **10** and **11**, the compounds were tested as potentiators on CFBE41o-cells kept for 24 h at 32 $^{\circ}$ C, in the presence of the specific CFTR inhibitor-172 (Fig. 6). The ion transport activity elicited by thiazoles **10**, **11** and VX-770 was completely abolished under these conditions, demonstrating the specific effects of test compounds on F508del CFTR-mediated ion transport (Fig. 6).

In silico ADME analysis

The evaluation of the pharmacokinetic properties of molecules designed to be eventually used in therapy is important in the early drug discovery phases. The theoretical absorption, distribution, metabolism and excretion (ADME) properties of compounds **1**–**16** were determined by *in silico* analysis, using the free online software SwissADME available at <http://www.swissadme.ch/index.php>.²⁷ The following




Fig. 5. Potentiator activity of novel thiazoles. The bar graphs report F508del-CFTR activity in CFBE41o-cells, incubated at 32 °C for 24 h to rescue defective mutant CFTR maturation, after acute treatment with hits, at the indicated concentrations. Activity was measured with the HS-YFP assay. The dotted lines indicate the level of activity in cells treated with forskolin alone (DMSO, negative control) and with the positive control, potentiator VX-770 (1 μM). Data are reported as mean \pm SD (n = 8). **P < 0.01, *P < 0.05 versus control (ANOVA with Dunnett's post hoc test).

physicochemical parameters, which according to Lipinski's rule of five indicate crucial characteristics for oral bioavailability, were evaluated: molecular weight (MW), calculated logarithm of the octanol-water partition coefficient (LogP), number of H-bond donors (nHBD), number of H-bond acceptors (nHBA) and number of rotatable bonds (nRB), together with the topological polar surface area (TPSA). Lipinski's rule of five states that, to be orally active, a small molecule should have MW \leq 500 Daltons, LogP \leq 5, nHBD \leq 5, nHBA \leq 10 and nRB \leq 10.^{28,29} Absorption and membrane permeability are also influenced by TPSA, which should be lower than 140 Å² to have intestinal absorption. The results are reported in Table 1 together with the values obtained for the reference compound VX-770. All the thiazole derivatives obey the Lipinski's rule and have a TPSA lower than 140 Å², thus suggesting good gastrointestinal absorption.

Finally, compounds 1–16 were not recognized by SwissADME software as PAINS (Pan Assay Interference compoundS), i.e. molecules containing substructures showing potent response in assays irrespective of the target. This evidence allows to exclude that the studied thiazole derivatives interact nonspecifically and yield false positive biological output.

Discussion

The results obtained allow to get some information about the effects of the thiazole derivatives here described as correctors or potentiators of F508del-CFTR. Although several thiazole-containing correctors have been described so far,^{9,16–18,19–23} when tested as correctors and compared with Lumacaftor™ (VX-809), none of the thiazole derivatives 1–16 showed significant effects, thus suggesting that the thiazole

nucleus of these compounds is not adequately decorated to obtain a corrector activity. On the other hand, considering the potentiator activity, two compounds emerged (10 and 11) that, although less effective than the positive control Ivacaftor™ (VX-770), significantly potentiated F508del-CFTR function. Interestingly, comparing the results obtained, it is possible to get some insights into the structural requirements necessary to achieve potentiator activity. In particular, the introduction of a halogen at para position of the phenyl group, led to an improvement of the activity. Indeed compound 9, bearing an unsubstituted phenyl group, was not active, whereas compounds 10 and 11, having as substituent chlorine and iodine, respectively, gave the best results as potentiators (Fig. 4). Furthermore, compounds 10 and 11 showed similar efficacy but slightly different potency (E_{\max} = 1.8, EC_{50} = 1.8 μM for compound 10; E_{\max} = 1.9, EC_{50} = 3.2 μM for compound 11), suggesting that both the halogen substituents contribute in enhancing the activity. Very important seems also the simultaneous presence of two ethyl groups, the one of the ester function and the other one at the benzamide nitrogen. Indeed, neither the ethyl esters 2 and 3, which do not have the benzamide nitrogen ethylated, nor the acidic derivatives 6 and 7, bearing an ethyl group only at the benzamide nitrogen, were active (Fig. 4).

Conclusion

In conclusion, although in the experimental model adopted the designed derivatives showed only poor activity as correctors, this preliminary study allowed to identify compounds 10 and 11, which proved to have the structural requirements necessary to express some biological effects as potentiators, thus suggesting that the studied scaffold,




Fig. 6. Specific activation of mutant F508del-CFTR by novel thiazoles. The bar graphs report F508del-CFTR activity in CFBE41o-cells, incubated at 32 °C for 24 h to rescue defective mutant CFTR maturation, after acute treatment with forskolin (fsk, 20 μM) plus vehicle alone (DMSO) or VX-770 (1 μM) or thiazoles (10 μM for both) in the absence or in the presence of inh-172 (15 μM). Activity was measured with the HS-YFP assay. The dotted lines indicate the level of activity in cells treated with forskolin plus vehicle. Data are reported as mean \pm SD (n = 8). ***P < 0.001 versus control (ANOVA with Dunnett's post hoc test).

Table 1ADME *in silico* analysis (data obtained by using SwissADME software).

Comp	MW	LogP	nHBD	nHBA	nRB	TPSA (Å ²)	GI absorption	PAINS alert
1	290.34	2.36	1	4	7	96.53	High	0
2	324.78	2.88	1	4	7	96.53	High	0
3	416.23	3.02	1	4	7	96.53	High	0
4	380.42	2.38	1	7	10	124.22	High	0
5	262.28	1.61	2	4	5	107.53	High	0
6	296.73	2.16	2	4	5	107.53	High	0
7	388.18	2.29	2	4	5	107.53	High	0
8	352.36	1.53	2	7	8	135.22	High	0
9	318.39	2.86	0	4	8	87.74	High	0
10	352.84	3.45	0	4	8	87.74	High	0
11	444.29	3.59	0	4	8	87.74	High	0
12	408.47	2.87	0	7	11	115.43	High	0
13	290.34	2.19	1	4	6	98.74	High	0
14	324.78	2.71	1	4	6	98.74	High	0
15	416.23	2.81	1	4	6	98.74	High	0
16	380.42	2.18	1	7	11	126.43	High	0
VX-770	392.49	4.47	3	3	5	82.19	High	0

MW: molecular weight; LogP: values correspond to Consensus LogP_{o/w}; nHBD: number of H-bond donors; nHBA: number of H-bond acceptors; nRB: number of rotatable bonds; TPSA: topological polar surface area; GI: gastrointestinal; PAINS: Pan Assay INterference compounds.

adequately substituted, enables to obtain F508del-CFTR potentiator activity. Interestingly, *in silico* ADME analysis showed that these thiazole derivatives do not violate the Lipinski's rule of five, therefore they are expected to have good oral bioavailability. Moreover, SwissADME software did not recognize them as PAINS, thus excluding nonspecific effects. On this basis, compounds **10** and **11** could represent a valuable starting point for the design of analogues characterized by improved CFTR potentiator activity and endowed with promising pharmacokinetic properties.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Work in N.P. lab is supported by the Italian Ministry of Health through Cinque per mille and Ricerca Corrente (Linea1), and by grants from the Fondazione per la Ricerca sulla Fibrosi Cistica (FFC no. 9/2017 with the contribution of “Delegazione FFC di Genova con Gruppo di Sostegno FFC di Savona Spotorno”, “Un fiore per Valeria [Assemini – Cagliari]”, “Gruppo di Sostegno FFC di Vigevano”, “Delegazione FFC della Valdadige”, and “Delegazione FFC di Lodi”; FFC no. 9/2019 with the contribution of “Delegazione FFC di Genova con Gruppo di Sostegno FFC di Savona Spotorno”, “Delegazione FFC di Valle Scrivia Alessandria”, “Delegazione FFC di Montescaglioso”, and “Delegazione FFC di Ascoli Piceno”).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bmc.2020.127473>.

References

- Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. *N Engl J Med*. 2015;372:351–362. <https://doi.org/10.1056/NEJMra1300109>.
- Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. *Trends Mol Med*. 2012;18:81–91. <https://doi.org/10.1016/j.molmed.2011.10.003>.
- Fukuda R, Okiyoned T. Peripheral protein quality control as a novel drug target for CFTR stabilizer. *Front Pharmacol*. 2018;9:1100. <https://doi.org/10.3389/fphar.2018.01100>.
- Hwang T-C, Kirk KL. The CFTR ion channel: gating, regulation, and anion permeation. *Cold Spring Harb Perspect Med*. 2013;3:a009498. <https://doi.org/10.1101/cshperspect.a009498>.
- Li H, Pesce E, Sheppard DN, Singh AK, Pedemonte N. Therapeutic approaches to CFTR dysfunction: from discovery to drug development. *J Cyst Fibros*. 2018;17(2S):S14–S21. <https://doi.org/10.1016/j.jcf.2017.08.013>.
- Van Goor F, Hadida S, Grootenhuis PDJ, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *PNAS*. 2011;108:18843–18848. <https://doi.org/10.1073/pnas.1105787108>.
- Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. *Proc Natl Acad Sci USA*. 2009;106:18825–18830. <https://doi.org/10.1073/pnas.0904709106>.
- Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. *N Engl J Med*. 2015;373:220–231. <https://doi.org/10.1056/NEJMoa1409547>.
- Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. *J Clin Invest*. 2005;115:2564–2571. <https://doi.org/10.1172/JCI24898>.
- Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. *ChemBioChem*. 2007;8:1012–1020. <https://doi.org/10.1002/cbic.200700027>.
- Kalid O, Mense M, Fischman S, et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. *J Comput Aided Mol Des*. 2010;24:971–991. <https://doi.org/10.1007/s10822-010-9390-0>.
- Odolczyk N, Fritsch J, Norez C, et al. Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain. *EMBO Mol Med*. 2013;5:1484–1501. <https://doi.org/10.1002/emmm.201302699>.
- Leoni A, Locatelli A, Morigi R, Rambaldi M. Novel thiazole derivatives: a patent review (2008–2012; Part 1). *Expert Opin Ther Pat*. 2014;24:201–216. <https://doi.org/10.1517/13543776.2014.858121>.
- Leoni A, Locatelli A, Morigi R, Rambaldi M. Novel thiazole derivatives: a patent review (2008–2012; Part 2). *Expert Opin Ther Pat*. 2014;24:759–777. <https://doi.org/10.1517/13543776.2014.910196>.
- Morigi R, Locatelli A, Leoni A, Rambaldi M. Recent patents on thiazole derivatives endowed with antitumor activity. *Recent Pat Anticancer Drug Discov*. 2015;10(3):280–297. <https://doi.org/10.2174/1574892810666150708110432>.
- Yu J, Yoo CL, Yang B, et al. Potent s-cis-locked bithiazole correctors of Delta F508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. *J Med Chem*. 2008;51:6044–6054. <https://doi.org/10.1021/jm800533c>.
- Ye L, Knapp JM, Sangwung P, Fetting JC, Verkman AS, Kurth MJ. Pyrazolylthiazole as ΔF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles. *J Med Chem*. 2010;53:3772–3781. <https://doi.org/10.1021/jm100235h>.
- Donald MB, Rodriguez KX, Shay H, Phuan PW, Verkman AS, Kurth MJ. Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis. *Bioorg Med Chem*. 2012;20:5247–5253. <https://doi.org/10.1016/j.bmc.2012.06.046>.
- Pedemonte N, Tomati V, Sondo E, et al. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. *J Biol Chem*. 2011;286:15215–15226. <https://doi.org/10.1074/jbc.M110.184267>.
- Pesce E, Bellotti M, Liessi N, et al. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis. *Eur J Med Chem*. 2015;99:14–35. <https://doi.org/10.1016/j.ejmech.2015.05.030>.

21. Liessi N, Cichero E, Pesce E, et al. Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools. *Eur J Med Chem.* 2018;144:179–200. <https://doi.org/10.1016/j.ejmech.2017.12.030>.
22. Tassini S, Sun L, Lanko K, et al. Discovery of multi-target agents active as broad-spectrum antivirals and correctors of cystic fibrosis transmembrane conductance regulator (CFTR) for associated pulmonary diseases. *J Med Chem.* 2017;60:1400–1416. <https://doi.org/10.1021/acs.jmedchem.6b01521>.
23. Tassini S, Langron E, Delang L, et al. Multitarget CFTR modulators endowed with multiple beneficial side effects for cystic fibrosis patients: toward a simplified therapeutic approach. *J Med Chem.* 2019;62:10833–10847. <https://doi.org/10.1021/acs.jmedchem.9b01416>.
24. Kumar Y, Green R, Borysko KZ, Wise DS, Wotring LL, Townsend LB. Synthesis of 2,4-disubstituted thiazoles and selenazoles as potential antitumor and antifilarial agents: 1. Methyl 4-(isothiocyanatomethyl)thiazole-2-carbamates, -selenazole-2- carbamates, and related derivatives. *J Med Chem.* 1993;36:3843–3848. <https://doi.org/10.1021/jm00076a012>.
25. Li L, Zhang C-L, Song H-R, Tan C-Y, Ding H-W, Jiang Y-Y. Discovery of novel dual inhibitors of VEGFR and PI3K kinases containing 2-ureidothiazole scaffold. *Chinese Chem Lett.* 2016;27:1–6. <https://doi.org/10.1016/j.ccllet.2015.09.008>.
26. Boehringer M, Zbinden K, Haap W et al., Heteroarylacetamide inhibitors of factor Xa, Pat. No: US 20060142362 A1, 2006.
27. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep.* 2017;7:42717. <https://doi.org/10.1038/srep42717>.
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev.* 1997;23:3–25. [https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1).
29. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov Today Technol.* 2004;1:337–341. <https://doi.org/10.1016/j.ddtec.2004.11.007>.